Olatunde Damilola, De Benedetti Arrigo
Department of Biochemistry and Molecular Biology, The Feist Weiller Cancer Center, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Cancers (Basel). 2024 Aug 22;16(16):2918. doi: 10.3390/cancers16162918.
Despite some advances in controlling the progression of prostate cancer (PCa) that is refractory to the use of ADT/ARSI, most patients eventually succumb to the disease, and there is a pressing need to understand the mechanisms that lead to the development of CRPC. A common mechanism is the ability to integrate AR signals from vanishing levels of testosterone, with the frequent participation of YAP as a co-activator, and pointing to the deregulation of the Hippo pathway as a major determinant. We have recently shown that YAP is post-transcriptionally activated via the TLK1>NEK1 axis by stabilizing phosphorylation at Y407. We are now solidifying this work by showing the following: (1) The phosphorylation of Y407 is critical for YAP retention/partition in the nuclei, and J54 (TLK1i) reverses this along with YAP-Y407 dephosphorylation. (2) The enhanced degradation of (cytoplasmic) YAP is increased by J54 counteracting its Enzalutamide-induced accumulation. (3) The basis for all these effects, including YAP nuclear retention, can be explained by the stronger association of pYAP-Y407 with its transcriptional co-activators, AR and TEAD1. (4) We demonstrate that ChIP for GFP-YAP-wt, but hardly for the GFP-YAP-Y407F mutant, at the promoters of typical ARE- and TEAD1-driven genes is readily detected but becomes displaced after treatment with J54. (5) While xenografts of LNCaP cells show rapid regression following treatment with ARSI+J54, in the VCaP model, driven by the oncogenic translocation, tumors initially respond well to the combination but subsequently recur, despite the continuous suppression of pNek1-T141 and pYAP-Y407. This suggests an alternative parallel pathway for CRPC progression for VCaP tumors in the long term, which may be separate from the observed ENZ-driven YAP deregulation, although clearly some YAP gene targets like PD-L1, that are found to accumulate following prolonged ENZ treatment, are still suppressed by the concomitant addition of J54.
尽管在控制对雄激素剥夺治疗(ADT)/雄激素受体抑制剂(ARSI)难治的前列腺癌(PCa)进展方面取得了一些进展,但大多数患者最终仍死于该疾病,因此迫切需要了解导致去势抵抗性前列腺癌(CRPC)发生发展的机制。一种常见机制是能够将来自睾酮水平消失的雄激素受体(AR)信号整合起来,YAP作为共激活因子频繁参与其中,这表明Hippo信号通路失调是一个主要决定因素。我们最近发现,YAP通过TLK1>NEK1轴在转录后被激活,即稳定Y407位点的磷酸化。我们现在通过以下研究来巩固这项工作:(1)Y407位点的磷酸化对于YAP在细胞核中的保留/分布至关重要,J54(TLK1抑制剂)通过使YAP - Y407去磷酸化来逆转这一过程。(2)J54通过抵消恩杂鲁胺诱导的(细胞质)YAP积累,增加了其降解。(3)所有这些效应的基础,包括YAP在细胞核中的保留,可以通过磷酸化的YAP - Y407与其转录共激活因子AR和TEAD1更强的结合来解释。(4)我们证明,在典型的雄激素反应元件(ARE)和TEAD1驱动基因的启动子处,GFP - YAP - wt的染色质免疫沉淀(ChIP)很容易检测到,但GFP - YAP - Y407F突变体几乎检测不到,而用J54处理后则被取代。(5)虽然LNCaP细胞异种移植瘤在用ARSI + J54治疗后迅速消退,但在由致癌易位驱动的VCaP模型中,肿瘤最初对联合治疗反应良好,但随后复发,尽管pNek1 - T141和pYAP - Y407持续受到抑制。这表明从长期来看,VCaP肿瘤的CRPC进展存在另一条平行途径,这可能与观察到的恩杂鲁胺驱动的YAP失调无关,尽管显然一些YAP基因靶点如程序性死亡配体1(PD - L1),在长期恩杂鲁胺治疗后被发现积累,但在同时添加J54后仍受到抑制。